CoronaVR
Predicted highly potential B cell epitopes
| No | Protein | Epitope sequence | Start | Stop | Length | Conservancy |
|---|---|---|---|---|---|---|
| 1 | N | TTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGD | 165 | 216 | 52 | 88.46% (SARS-CoV) |
| 2 | N | HGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLS | 59 | 105 | 47 | 89.36% (SARS-CoV) |
| 3 | N | DAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDD | 358 | 402 | 45 | 88.89% (SARS-CoV) |
| 4 | N | RLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKA | 226 | 267 | 42 | 95.24% (SARS-CoV) |
| 5 | N | FGGPSDSTGSNQNGERSGARSKQRRPQGLPNN | 17 | 48 | 32 | 81.25% (SARS-CoV) |
| 6 | N | RRGPEQTQGNFGDQELIRQGTDYK | 276 | 299 | 24 | 95.83% (SARS-CoV) |
| 7 | N | SKQLQQSMSSADS | 404 | 416 | 13 | 61.54% (SARS-CoV) |
| 8 | N | DPNFKD | 343 | 348 | 6 | 83.33% (SARS-CoV) |
| 9 | S | YNSASFSTFKCYGVSPTKLNDLCFT | 369 | 393 | 25 | 84% (SARS-CoV) |
| 10 | S | GDEVRQIAPGQTGKIADYNYKLP | 404 | 426 | 23 | 91.3% (SARS-CoV) |
| 11 | S | KHTPINLVRDLPQGFS | 206 | 221 | 16 | 56.25% (SARS-CoV) |
| 12 | S | VNNSYECDIPI | 656 | 666 | 11 | 81.82% (SARS-CoV) |
| 13 | E | YVYSRVKNLNSSRVP | 57 | 71 | 15 | 80% (SARS-CoV) |
| 14 | Leader protein (NSP1) | LPVLQV | 18 | 23 | 6 | 100% (SARS-CoV) |
| 15 | Leader protein (NSP1) | KNGNKGAGGHSYGADLKSFDLGDELGTDPYEDFQENWNTKHSSGV | 125 | 169 | 45 | 82.22% (SARS-CoV) |
| 16 | NSP2 | AGKASC | 208 | 213 | 6 | 66.67% (SARS-CoV), 66.67% (MERS-CoV), 66.67% (NL63), 66.67% (229E) |
| 17 | NSP2 | CHNSEVGPEH | 373 | 382 | 10 | 60% (SARS-CoV) |
| 18 | NSP2 | LQKEKVNINIVGDFKLNE | 454 | 471 | 18 | 77.78% (SARS-CoV) |
| 19 | NSP2 | VTKGKAKKGAWNIGEQKSILS | 511 | 531 | 21 | 71.43% (SARS-CoV) |
| 20 | NSP2/NSP3 | FTLKGGAP | 813 | 820 | 8 | 87.5% (SARS-CoV), 87.5% (MERS-CoV) |
| 21 | NSP3 | LYIDINGNLHPDSATLVSDIDITFLKKDAPYIVGDVVQEGVLT | 1255 | 1297 | 43 | 51.16% (SARS-CoV) |
| 22 | NSP3 | GLNGYTVEE | 1333 | 1341 | 9 | 66.67% (SARS-CoV) |
| 23 | NSP3 | YILPSIISNEKQE | 1354 | 1366 | 13 | 53.85% (SARS-CoV) |
| 24 | NSP3 | IVSTIQRKYKGIKIQEGVVD | 1398 | 1417 | 20 | 85% (SARS-CoV) |
| 25 | NSP3 | GLNLEEAARYMRS | 1456 | 1468 | 13 | 84.62% (SARS-CoV) |
| 26 | NSP3 | SYKDWSYSGQ | 1510 | 1519 | 10 | 90% (SARS-CoV) |
| 27 | NSP3 | FDNLKTLLSLREV | 1553 | 1565 | 13 | 76.92% (SARS-CoV) |
| 28 | NSP3 | EQFKKGVQIPCTC | 1777 | 1789 | 13 | 53.85% (SARS-CoV) |
| 29 | NSP3 | TYKLDGVVCTEIDPKLDNYYKKDNSYFTEQPIDLVPNQPYPNASF | 1881 | 1925 | 45 | 80% (SARS-CoV) |
| 30 | NSP3 | FPDLNG | 1960 | 1965 | 6 | 100% (SARS-CoV) |
| 31 | NSP3 | KHYTPSFKKGAK | 1973 | 1984 | 12 | 75% (SARS-CoV) |
| 32 | NSP3 | GMPSYCTGYREGYLNSTNVTIATY | 2258 | 2281 | 24 | 62.5% (SARS-CoV) |
| 33 | NSP3 | SSFKWD | 2312 | 2317 | 6 | 66.67% (SARS-CoV), 66.67% (OC43), 66.67% (NL63), 66.67% (HKU1) |
| 34 | NSP3 | TRQVVNV | 2747 | 2753 | 7 | 100% (SARS-CoV) |
| 35 | NSP4 | DFDTWFSQRGGSYTNDK | 2833 | 2849 | 17 | 82.35% (SARS-CoV) |
| 36 | NSP4 | TNVLEGSVAYESLRPDTRYVLM | 2936 | 2957 | 22 | 77.27% (SARS-CoV) |
| 37 | 3C-like proteinase (NSP5) | MAFPSGK | 3269 | 3275 | 7 | 100% (SARS-CoV) |
| 38 | 3C-like proteinase (NSP5) | YNYEPLTQDH | 3500 | 3509 | 10 | 100% (SARS-CoV) |
| 39 | NSP7 | VQSKMSD | 3858 | 3864 | 7 | 100% (SARS-CoV) |
| 40 | NSP8/ NSP9 | KLQNNELSPVAL | 4138 | 4149 | 12 | 100% (SARS-CoV) |
| 41 | RDRP (NSP12) | PCGTGTSTDV | 4413 | 4422 | 10 | 100% (SARS-CoV) |
| 42 | RDRP (NSP12) | FQEKDEDDNL | 4448 | 4457 | 10 | 80% (SARS-CoV) |
| 43 | RDRP (NSP12) | TFSNYQHEET | 4468 | 4477 | 10 | 90% (SARS-CoV) |
| 44 | RDRP (NSP12) | QDLNGNWYDFGDFIQTTPGSGVP | 4602 | 4624 | 23 | 82.61% (SARS-CoV) |
| 45 | RDRP (NSP12) | VAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVEL | 4797 | 4829 | 33 | 100% (SARS-CoV), 81.82% (MERS-CoV) |
| 46 | RDRP (NSP12) | LKYAISAKNR | 4936 | 4945 | 10 | 100% (SARS-CoV), 100% (MERS-CoV), 100% (OC43), 100% (HKU1), 80% (229E), 80% (NL63) |
| 47 | RDRP (NSP12) | KPGGTSSGDATT | 5068 | 5079 | 12 | 100% (SARS-CoV), 100% (MERS-CoV), 100% (OC43), 100% (HKU1), 91.67% (229E), 83.33% (NL63) |
| 48 | RDRP (NSP12) | WTETDLTKGP | 5192 | 5201 | 10 | 100% (SARS-CoV) |
| 49 | Helicase (NSP13) | TCVGSDNVTDFNAIATCDWTNAGDYILANTCTE | 5420 | 5452 | 33 | 100% (SARS-CoV) |
| 50 | Helicase (NSP13) | FEKGDYG | 5524 | 5530 | 7 | 100% (SARS-CoV), 85.71% (HKU1) |
| 51 | Helicase (NSP13) | PAPRTLLTKGTLEPE | 5730 | 5744 | 15 | 100% (SARS-CoV) |
| 52 | Helicase (NSP13) | LYDKLQ | 5905 | 5910 | 6 | 100% (SARS-CoV) |
| 53 | Helicase/ 3'-5' Exonuclease | RNVATLQAENVTG | 5919 | 5931 | 13 | 100% (SARS-CoV) |
| 54 | 3'-5' Exonuclease (NSP14) | PNNTDFSRVSAKPPPGDQF | 6053 | 6071 | 19 | 78.95% (SARS-CoV) |
| 55 | 3'-5' Exonuclease (NSP14) | MYKGLPW | 6078 | 6084 | 7 | 100% (SARS-CoV) |
| 56 | 3'-5' Exonuclease (NSP14) | GFTGNLQSNHDLYCQVHGNAHVA | 6173 | 6195 | 23 | 91.3% (SARS-CoV) |
| 57 | EndoRNAse (NSP15) | KGHFDGQQG | 6464 | 6472 | 9 | 77.78% (SARS-CoV) |
| 58 | EndoRNAse (NSP15) | YKRDAPAHIS | 6540 | 6549 | 10 | 80% (SARS-CoV) |
| 59 | EndoRNAse (NSP15) | SVKGLQPSVGPK | 6599 | 6610 | 12 | 75% (SARS-CoV) |
| 60 | 2'-O- ribose methyltransferase (NSP16) | DKGVAP | 6873 | 6878 | 6 | 100% (SARS-CoV), 100% (NL63), 83.33% (MERS-CoV), 83.33% (OC43), 83.33% (HKU1), 83.33% (229E) |
| 61 | 2'-O- ribose methyltransferase (NSP16) | IQLSSYSLFDMSKFPLKLRG | 7035 | 7054 | 20 | 100% (SARS-CoV) |
| 62 | ORF3a | KIITLKKRWQL | 61 | 71 | 11 | 81.82% (SARS-CoV) |
| 63 | ORF7a | VKHVYQLRARSVSPKLFIRQEEVQEL | 71 | 96 | 26 | 80.77% (SARS-CoV) |
| 64 | ORF7b | ELQDHNE | 33 | 39 | 7 | 57.1% (SARS-CoV) |
| 65 | ORF8 | DEAGSKSPIQYIDIGN | 63 | 78 | 16 | 18.75% (SARS-CoV) |